ABOUT CATALENT

• Formed in 2007 through the acquisition of Cardinal Health by Blackstone Group, Catalent claims to be the number one global partner for pharmaceuticals, biologics and consumer health innovations.
• Currently operating from 17 sites across Asia, Europe and the Americas, Catalent provides product development, launch and full lifecycle supply around the world.
• The company employs over 19,000 people, with more than 2,500 scientists and technicians. It has over 1,000 partner programmes and launches 150 new products a year.
• One sector of Catalent’s business is Consumer Health, covering global, over-the-counter, nutritional supplement and beauty industries. Catalent claims it is a global leader in softgel technology with over 85 years in the industry. It supplies over 60 billion softgels annually.
• Commercially available Catalent Consumer Health products include: OptiGel Mini Softgel Capsules, EasyBurst Chewable Softgels, Vegicaps Capsules and CosmoPod Unit-Dose Capsules. The latter is ideal for single-dose, topical beauty solutions, while the Vegicaps tap into the growing inner beauty movement.
• The CosmoPod capsule range is derived from carrageenan, an all-natural, plant-based Seaweed extract.
• Catalent Consumer Health produces more than 5,000 consumer health and beauty products, marketed in more than 70 countries.
• In 2020, Catalent expanded its Consumer Health manufacturing facilities with a USD 3.2 million investment in Strathroy, Canada, and Sorocaba, Brazil.
• Catalent states that 97% of its Consumer Health sites operate with renewable energy.